stockrowWAVE Life Sciences Ltd.
WAVE Life Sciences Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42.7 million, down 60.5% from fiscal 2024.
- Revenue
- +73.0%
- EPS
- +5.25%
- Free cash flow
- −33.9%
Quarter to September 2026, against a year earlier
Follow WVE
Alert me
WAVE Life Sciences Ltd. (WVE) EV/Sales
As of 6 November 2026, WAVE Life Sciences Ltd. (WVE) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from −0.9× (March 2022) to 1,050× (September 2016); the current reading is higher than 17% of that period. That is below the Biotechnology industry median of 9.0× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 53.0× | 307.63% |
| FY2024 | 13.0× | 302.35% |
| FY2023 | 3.2× | (97.05%) |
| FY2022 | 110× | 45,282.92% |
| FY2021 | 0.2× | (96.09%) |
| FY2020 | 6.2× | (20.53%) |
| FY2019 | 7.8× | (89.24%) |
| FY2018 | 72.4× | (63.89%) |
| FY2017 | 200× | (51.05%) |
| FY2016 | 409× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 4.6× | (56.89%) |
| Jun 2026 | 10.6× | (15.84%) |
| Mar 2026 | 12.6× | (76.18%) |
| Dec 2025 | 53.0× | 461.28% |
| 40 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HELP Cybin Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. | 3.6× |
| ZVRA Zevra Therapeutics, Inc. compare | 4.0× |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.7× |
| ACHV Achieve Life Sciences, Inc. compare | 29.0× |
| DBVT DBV Technologies S.A. compare | 211× |
| CADL Candel Therapeutics, Inc. compare | 3,940× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)